KLRC1 and neoplasm: While NKG2A blockade monotherapy had no impact on tumor growth nor mouse survival, in combination with KVK vaccination, it significantly increased the antitumoral efficacy resulting in 57% of complete responders and the median survival was not reached (Figure 1B,C).